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Protein kinase C-delta (PKCd), a marker of
inflammation and tuberculosis diseaseprogression
in humans, is important for optimal macrophage
killing effector functions and survival in mice
This article has been corrected since Advance Online Publication and an erratum is also printed in this issue
SP Parihar1,2, M Ozturk1,2, MJ Marakalala1, DT Loots3, R Hurdayal1,2,4, D Beukes3,
M Van Reenen3, DE Zak5, SK Mbandi6, F Darboe6, A Penn-Nicholson6, WA Hanekom6, M Leitges7,
TJ Scriba6, R Guler1,2 and F Brombacher1,2
We previously demonstrated that protein kinase C-d (PKCd) is critical for immunity against Listeria monocytogenes,
Leishmania major, and Candida albicans infection in mice. However, the functional relevance of PKCd during
Mycobacterium tuberculosis (Mtb) infection is unknown. PKCdwas significantly upregulated in whole blood of patients
with active tuberculosis (TB) disease. Lung proteomics further revealed that PKCdwas highly abundant in the necrotic
and cavitory regions of TB granulomas in multidrug-resistant human participants. In murine Mtb infection studies,
PKCd / micewere highly susceptible to tuberculosiswith increasedmortality, weight loss, exacerbated lungpathology,
uncontrolledproinflammatorycytokine responses,and increasedmycobacterialburdens.Moreover, thesemicedisplayed
a significant reduction in alveolar macrophages, dendritic cells, and decreased accumulation of lipid bodies (lungs and
macrophages) and serum fatty acids. Furthermore, a peptide inhibitor of PKCd in wild-type mice mirrored lung
inflammation identical to infected PKCd / mice. Mechanistically, increased bacterial growth in macrophages from
PKCd / mice was associated with a decline in killing effector functions independent of phagosome maturation and
autophagy. Taken together, these data suggest that PKCd is amarker of inflammation during active TB disease in humans
and required for optimal macrophage killing effector functions and host protection during Mtb infection in mice.
INTRODUCTION
Protein kinase C-d (PKCd) plays a multitude of physiological
roles through its ability to phosphorylate multiple target
proteins involved in various cellular processes such as signal
transduction,1 apoptosis,2 proliferation and survival,3 tran-
scription,4 hormonal regulation,5 and immune responses.6,7
PKCd / mice were originally characterized by two inde-
pendent research groups who highlighted the role of this
kinase in B-cell anergy8 and B cell-mediated autoimmunity.9
Furthermore, PKCd / mice were protected against glucose
intolerance induced by high-fat diet by exhibiting reduced
accumulation of liver triacylglycerol and impaired production
of lipogenic enzymes.10 This feature of accumulating fewer
lipids during an inflammatory condition by PKCd / mice
uponMycobacterium tuberculosis (Mtb) infectionmight impair
its ability to undergo slow-replicating, persistence phase as
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reported in human sputum.11 Lipids are a prerequisite for the
persistence of Mtb in macrophages that transforms them into
foamy macrophages that contribute to tissue pathology and
facilitate dissemination.12
Most studies on the role of PKCd were performed using
inhibitors in vitro that lacked in specificity to a particular PKC
isoform. A frequently used chemical rottlerin, which is a
nonspecific chemical inhibitor of PKCd to block enzymatic
reactions and intracellular signaling in pancreatic acinar
cells.13 Rottlerin was shown to reduce viral burdens in
human monocyte-derived macrophages during the early
stages of HIV-1 infection.14 Physiologically, silencing of
PKCd with anti-PKCd small interfering RNA resulted in
increased cholesterol efflux in hamster kidney cells and
a murine macrophage cell line RAW264.7.15 Moreover,
PKC isoforms such as d and e are required for phagocytosis
in RAW264.7 macrophages,16 and PKCe also regulates
autocrine production of tumor necrosis factor (TNF) that
in turn induces apoptosis in lipopolysaccharide-activated
macrophages.17
Figure1 Increasedexpressionof protein kinase-Cd (PKCd) in humanwhole blood, lungsof tuberculosis (TB) patients, andMycobacterium tuberculosis
(Mtb)-infected macrophages. (a) PKCd mRNA expression in TB progressors, expressed as log2 fold change over matched controls, from Adolescent
Cohort Study (ACS) group. The dotted line represents the mean log2 fold change, nonlinear spline function in 46 progressors and 107 healthy
QuantiFERON (QFT)-positive controls. The blue shaded area represents 99% confidence intervals. (b) mRNA expression of PKCd measured in an
independentQFT-negative or -positive controls, or patientswith activeTBdisease, fromACSgroup ina (n¼ 8–16). (c) PKCdmRNAexpression validated
by quantitative reverse transcription–PCR (qRT-PCR) in whole blood from SHIP cohort in adults with active TB disease before the initiation of drug
treatment (n¼ 30) or QFT-positive healthy controls (n¼ 30, LTBI, latentMtb infection). (d) PKCdmRNA expression in monocyte-derived macrophages
(MDMs) of healthy donors after Mtb infection in vitro (n¼2). (e) mRNA expression of PKC isoforms following the onset of antitubercular treatment in
humanTBpatients (n¼ 27). (f) Heatmap of z-score and log2-transformed label-free quantification of PKCd in different types of granulomas, excised from
patients infected with multidrug-resistantMtb (n¼ 5). Data are represented as mean±s.e.m., analyzed using unpaired Student’s t-test (c) and one-way
analysis of variance (ANOVA) (b–e), *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001 vs. control.
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Studies have suggested a functional role for PKCd in
regulating immunity to infectious diseases in vivo. Previously,
using PKCd / mice, we demonstrated a crucial role of this
kinase in macrophage-mediated phagosomal clearance of the
intracellular bacterium, Listeria monocytogenes.7 We further
reported that PKCd regulates the production of interleukin-12
(IL-12) p40/70 in both macrophages and dendritic cells,
required for protective Thelper cell type 1 immune responses in
a murine model of cutaneous leishmaniasis.6 We also
demonstrated that deletion of PKCd renders mice susceptible
to Candida albicans infection via Card9-mediated antifungal
immunity.18 These studies highlighted the key role of PKCd in
the immune response to infectious diseases. However, the
functional significance of PKCd in humans andmice alongwith
its effect on lipid homeostasis in host immunity to tuberculosis
(TB) infection has not been studied yet.
Here, we report that PKCdmRNA expression is increased in
peripheral blood of participants with active TB. In addition,
proteomic analysis of lung tissues from treatment-refractory
TB patients revealed higher levels of PKCd protein expression
in caseous and necrotic regions of cavitory granulomas,
highlighting that PKCd might be an indicator of an inflam-
mation. We further demonstrate that deletion of PKCd in
mice has a detrimental effect on a host with increased bacterial
loads, enhanced lung pathology, and mortality. Moreover,
PKCd is critical for the accumulation of lipid bodies in
macrophages and lungs duringMtb infection. Mechanistically,
PKCd is important for optimal macrophage killing effector
functions, independent of phagosome maturation and
autophagy.
RESULTS
Increased expression of PKCd during active TB disease
Recently, we identified a transcriptomic signature that has the
potential to distinguish latent infection from the development
of active disease.19 Given the pivotal role of PKCd in signal
transduction, we asked whether expression of this kinase
changes during the transition fromMtb infection to TB disease.
We analyzed gene expression data inwhole blood from a nested
control study correlating risk of TB from 800 days before
diagnosis. This included 46 adolescents with latent Mtb
infection who progressed to active disease (progressors)
and 107 adolescents with Mtb infection who remained
healthy.19 PKCd was significantly upregulated in progressors
when compared with latently infected healthy controls
(Figure 1a). Although two PKC isoforms (y and Z)
exhibited downregulation during progression to active TB
disease, the expression levels of other PKC isoforms (a, b, g, i, e,
and z) remained constant (Supplementary Figure S1 online).
This highlighted PKCd as a possible marker of active TB
disease that we sought to validate using quantitative real time–
PCR (qRT-PCR). PKCd mRNA expression was significantly
higher in whole blood from 8 participants with pulmonary
TB disease when compared with 16 QFT healthy controls
(QFT ) but notwith latentMtb infection (QFTþ ) (Figure 1b).
However, the latter was also significantly higher in whole
blood of a larger independent Strategic Health Innovation
Partnerships (SHIP) cohort of 30 active TB participants
and 30 healthy individuals (QFTþ ) with latent Mtb infec-
tion (Figure 1c). In addition, human monocyte-derived
macrophages (MDMs) also upregulated PKCd expression
following Mtb infection (Figure 1d). Collectively, these data
indicate that PKCd expression increases during active TB
disease and in vitro Mtb infection of macrophages.
We then explored whether anti-TB therapy would
decrease PKCd expression. We analyzed a publicly
available data set from an independent study20 that reported
whole-blood expression profiles of 27 first-time TB patients
before and after treatment. We found that PKCd was the
most abundantly expressed isoform compared with other
PKC isoforms. Importantly, the expression decreased from
week 1 to 26 weeks of successful treatment with TB therapy
(Figure 1e). Of note, all other PKC isoforms remained
unchanged before and after TB therapy except PKCy that
was marginally increased only at completion of treatment
(Figure 1e). This decline in PKCd expression after treatment
suggests that it might be an important component or
mediator of the host immune response during active TB
disease.
PKCd is highly expressed in necrotic and cavitary regions
of granulomas in patients with multidrug-resistant TB
We recently characterized proteomic signatures in various
regions of granulomas from treatment-refractory TB patients
who had undergone pneumonectomy due to severe lung
damage.21 Using the proteomics data, we determined the
protein expression levels of various PKC isoforms. Our analysis
revealed that only PKCd was associated with the necrotic
regions of both caseous and cavitary granulomas (Figure 1f),
whereas other PKC isoforms were largely absent in the lung
tissue samples (data not shown). This suggests an association of
PKCd within the regions of Mtb-specific host immune
responses at the site of disease. The abundance of PKCd
protein at the sites of exaggerated disease strengthens our
transcriptomic findings in whole blood, highlighting PKCd as a
host factor that is induced during the progression of cellular to
necrotic granulomas in humans.
PKCd is critical for host survival against Mtb infection in
mice
To further investigate how PKCd influences host mortality
during Mtb-infection, we compared PKCd / mice6,7 with
wild-type controls in a murine model of experimental TB.
Deletion of PKCd rendered mice highly susceptible to various
doses of intranasal Mtb infection (Figure 2a,d,g). Earlier and
increased mortality was associated with rapid weight loss
(Figure 2b,e,h) and increased bacterial titers in the lungs and
spleen determined at the time of killing (Figure 2c,f,i). Thus,
PKCd deficiency in mice results in increased bacterial burdens
and mortality during Mtb infection.
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Exacerbated histopathology and reduced accumulation of
lipid bodies in the lungs of PKCd / mice during Mtb
infection
As PKCdmice succumbed toMtb infection as early as 4 weeks
in mortality studies (Figure 2d), we performed an in-depth
analysis of disease parameters at 4 and 8 weeks using a dose of
1,000 colony-forming units (CFU). At 4 and 8 weeks after
infection, PKCd / mice displayed higher lung and spleen
burdens (Figure 3a), corroborating the mortality findings.
Susceptibility to infection in PKCd / mice was further
accompanied by a significant increase in lung inflammation as
revealed by lung weight index (Figure 3b), higher pulmonary
cell recruitment (Figure 3c), and larger lesion area in
hematoxylin and eosin-stained lung sections at 4 and 8
weeks after infection (Figure 3d). Furthermore,
immunohistochemistry revealed that inducible nitric oxide
synthase (iNOS) production was significantly increased in the
lungs of PKCd / mice, concomitant with increased
pulmonary tissue pathology indicating that PKCd might
directly or indirectly contribute to the control of lung
pathology (Figure 3e). Given the importance of PKCd in
the accumulation of cholesterol in human monocyte-derived
macrophages,22 we investigated lipid accumulation in the lungs
of PKCd / mice. Oil Red O staining of lung tissue sections of
PKCd / mice displayed significantly reduced accumulation
of lipids in lungs when compared with wild-type animals after 4
and 8 weeks of infection (Figure 3f). We next assessed whether
inhibiting PKCd in wild-type mice using a specific peptide
inhibitor TatVd1.1 (ref. 23) would recapitulate exaggerated
lung pathology of PKCd / mice following Mtb infection.
Indeed, mice treated with TatVd1.1 had significantly higher
lung weight index and more inflamed lung sections and lesion
size when compared with wild-type animals (Supplementary
Figure S2a–c). Together, these results demonstrate that
absence of PKCd in Mtb infection resulted in exacerbated
pathology and reduced accumulation of lipids in the lungs.
Figure 2 Protein kinase-Cd-deficient (PKCd / ) mice displayed enhanced mortality and mycobacterial burdens. Mice were infected with a range of
Mycobacterium tuberculosis (Mtb) (H37Rv) doses via intranasal challenge for mortality studies. Survival curve, body weight change, and lung bacterial
burden determined at the time of killing. (a–c) A total of 5,000 colony-forming units (CFUs) after 6 weeks; (d–f) 1,000 CFUs after 8 weeks; and (g–i) 350
CFUs after 18 weeks. Mortality curves were analyzed by Kaplan–Meyer survival test, **Po0.01, ***Po0.001 vs. wild-type (WT) control mice. Data are
represented as mean±s.e.m. of 9–10 mice/group, analyzed using unpaired Student’s t-test, *Po0.05, **Po0.01, ***Po0.001 vs. control.
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Figure 3 Protein kinase-Cd-deficient (PKCd / ) mice displayed increased lung pathology and nitric oxide and decreased lipid accumulation in the
lungs. Mice were infected with Mycobacterium tuberculosis (Mtb) (1,000 colony-forming units (CFUs)) via intranasal challenge. (a) Bacterial burden in
lungs and spleens, (b, c) lung weight index, as a proxy for inflammation, and (c) total number of cells harvested. (d–f) Representative images and
quantification of histopathology, (d) hematoxylin and eosin (H&E) staining and lesions, (e) immunohistochemistry for inducible nitric oxide synthase
(iNOS), and (f) Oil RedO staining for lipids in the lungs at 4 and 8weeks after infection. Data are represented asmean±s.e.m. of n¼ 4–5mice/group and
are representative of two independent experiments. Data are analyzed using unpaired, Student’s t-test, *Po0.05, **Po0.01, ***Po0.001, vs. wild-type
(WT) control.
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Increased proinflammatory cytokine responses in the
lungs of PKCd / mice following Mtb infection
Following excessive lung pathology and increased bacterial
loads in PKCd / mice (Figure 3d), we measured the
proinflammatory cytokines in the lungs of mice. Compared
with wild-typemice, PKCd / mice showedmarked increases
in proinflammatory cytokines including interferon (IFN)-g,
TNF, IL-1b, IFN-b, and IL-6 withminor effect on IL-10 at week
4 (Figure 4a) and week 8 (Figure 4b) after infection. In
the lungs of wild-type mice, the extent of proinflammatory
cytokines response is Mtb infection dose dependent (Supple-
mentary Figure S5f). Furthermore, flow cytometric analysis of
various pulmonary immune cell populations in PKCd /
mice after 4 and 8 weeks of infection demonstrated that
frequencies and total cell numbers of alveolar macrophages
(Figure 4c,f,i,l) and dendritic cells (Figure 4d,g,j,m) were
significantly decreased with concomitant increase in activated
macrophages (Figure 4g) when compared with wild-typemice.
Of note, we observed no major differences in the frequencies
and cell numbers of lymphocytes (CD4þ , CD8þ T and B cells)
(Figure 4e,h,k,n) or neutrophils (Figure 4c,f,i,l) infiltrating the
lung. Gating strategy defining myeloid cell populations in the
lungs are shown (Supplementary Figure S2d). In addition, we
showed that percentages of T cells were decreased and that of
dendritic cells were increased in thoracic lymph nodes at week 4
(Supplementary Figure S3a–d) but not at week 8 after
infection (Supplementary Figure S3e–h). Together, these
results indicated that the absence of PKCd increased inflam-
matory cytokine responses and decreased alveolar macro-
phages and dendritic cells in lungs of Mtb-infected mice.
Decreased fatty acids in serum of PKCd / mice following
Mtb infection
Decreased lipid accumulation in lungs of PKCd / mice
during Mtb infection prompted us to perform a total
metabolome extraction of the serum in these animals. Principal
component analysis showed a clear differentiation between
Mtb-infected (1,000 CFUs) wild-type and PKCd / mice at
week 4 (62% variance) and week 8 (64% variance) after
infection, respectively (Figure 5a,b). Metabolite profiles of
these two groups thus varied significantly to allow a natural
grouping of the individual samples. Fatty acids are determined
to be of significance via univariate and multivariate statistical
analysis presented inTables 1 and 2 . Considering these results,
Mtb-infected PKCd / mice showed significantly decreased
levels of all serum fatty acids when compared with wild-type
mice, except for mead acid, an elevation of which is a well-
known marker for fatty acid deficiencies.24 Here, we selectively
report that host-protective (arachidonic acid, a-linoleic acid,
and palmitic acid)25 and host-detrimental (behenic acid,
cervonic acid/docosahexaenoic acid, and timnodonic acid/
eicosapentaenoic acid)25 fatty acids were significantly lower in
the PKCd / mice during Mtb infection (Figure 5c,d). To
assess whether the observed effect was indeed PKCd specific
and not a consequence of morbidity and pathology at this
dose resulted in reduced food/water intake, we performed
metabolomics at a low dose (70CFUs) and found similar results
(Supplementary Figure S5a–d) as with 1,000 CFUs (Figure 5).
Notably, we confirmed that the changes in lipid profiles
were not a function of bacterial loads in the lungs of wild-type
mice (Supplementary Figure S5e). Thus, the absence of
PKCd led to a marginal decrease in serum fatty acids of
Mtb-infected mice.
Macrophages deficient in PKCd exhibit reduced
mycobacterial killing capacity and reduced accumulation
of lipid bodies
Using our publically available data set from CAGE sequencing
of macrophages infected with a hypervirulent Mtb strain
(HN878),26 we reported that PKCd in the murine bone
marrow-derivedmacrophages (BMDMs) was also upregulated,
whereas other PKC isoforms (except b) remained largely
unaffected (Figure 6a), PKCd expression was also validated
by qRT-PCR in murine macrophages (Supplementary
Figure S4a). Given the entire study was performed with an
H37Rv strain of Mtb, we measured the expression of PKCd in
H37Rv-infected macrophages (Figure 6b) that had slightly
different kinetics at 24 h after infection when compared with
HN878-infected macrophages (Figure 6a and Supplementary
Figure S4a). This discrepancy in expression kinetics at 24 h
was most likely due to the different strains of Mtb. We next
investigated the intracellular growth of Mtb in PKCd /
macrophages. Mycobacterial growth was significantly
increased in PKCd / macrophages particularly at 3 and 6
days after infection (Figure 6c) as well as in wild-type
macrophages transfected with anti-PKCd small interfering
RNA at 48 h after infection (Supplementary Figure S4b).
In PKCd / mice, we found a reduced accumulation of the
lipid bodies in the Mtb-infected lungs. Similarly, PKCd /
macrophages displayed fewer lipid bodies revealed by the
Oil Red O staining (red) in fluorescent microscopy in a
time-dependent manner concomitant with significantly higher
bacterial numbers (Rv-GFP, green) (Figure 6d,e). Unlike
in the in vivo model, we found no differences in cytokine
production by PKCd / BMDMs except for a significant
decrease in IL-6 (Figure 6f–i) , suggesting other cell popula-
tions contributed in the lungs. Thus, PKCd is important for
macrophage-mediated containment of mycobacteria and lipid
accumulation.
Killing effector functions in Mtb-infected PKCd /
macrophages
The PKC isoforms, including b27 and a,28 were reported to be
important for maturation of Mtb-containing phagosomes.
In bacterial infection, we previously reported that PKCd is
critical for containment of L. monocytogenes in phagosomes
of macrophages.7 Surprisingly inMtb infection, no differences
in the analyzed phagosome markers including LAMP-1,
LAMP-3, Cathepsin-D, and an autophagy marker LC3-II
were observed between PKCd / and control macrophages
(Figure 7a,b). This result suggests that PKCd is dispensable
for phagosome and autophagy-mediated killing of Mtb in
macrophages.
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Figure 4 Increased proinflammatory cytokine responses and the immune cell populations in the lungs of protein kinase-Cd-deficient (PKCd / ) mice
followingMycobacterium tuberculosis (Mtb) infection. (a,b) Supernatants from lung homogenateswere analyzed for interferon-g (IFN-g), tumor necrosis
factor (TNF), interleukin (IL)-1b, IL-10, and IFN-b using enzyme-linked immunosorbent assay (ELISA) after 4 and 8 weeks ofMtb infection. Single-cell
suspension of lung tissue was analyzed for percentage and total cell numbers of immune cell populations at 4 (c–h) and 8 (i–n) weeks after infection.
Surfacemarkers of different cell populations areas follows:B cells¼CD19þCD3 ,CD4þ Tcells¼CD3þCD4þ , CD8þ Tcells¼CD3þCD8þ , Alveolar
Mphs¼SiglecFþCD11cþAutoflourescenceþ , Activated Mphs¼CD11bþMHCIIþCD11c , DCs¼CD11cþMHCIIþCD11bþ , and Neutrophils¼
Gr1þCD11c . Data are represented asmean±s.e.m. ofn¼ 4–5mice/group andare representative of two independent experiments.Data are analyzed
using unpaired Student’s t-test, *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001, vs. wild-type (WT) control mice. Act, activated; Alv, alveolar; Mph,
macrophage.
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As the intracellular killing of Mtb is enhanced by nitrogen
and oxygen species,29 we measured the ability of isolated
macrophages to release reactive oxygen species (ROS),
hydrogen peroxide (H2O2), and nitric oxide (NO). We found
NO production was significantly decreased in PKCd /
macrophages at the protein level (Figure 7c) and mRNA level
using qRT-PCR (Figure 7d). In addition to NO, the release of
H2O2 (Figure 7e) and ROS (Figure 7f) was also significantly
decreased in the PKCd / macrophages. Furthermore, the
absence of PKCd in macrophages during Mtb infection also
renders them more prone to apoptosis, revealed by Annexin V
and 7-aminoactinomycinD staining (Figure 7g).Moreover, we
also evaluated the possible effect of antimicrobial molecules
secreted into the cell supernatant byMtb-infectedmacrophages
by incubating infected PKCd / cells with supernatants from
wild-type cells, and vice versa. Supernatant from infected
wild-type macrophages indeed reduced bacterial growth in
Mtb-infected PKCd / macrophages (Figure 7h). This
indicates that a deficiency of PKCd decreases optimal
oxidative and nitrosative killing effector functions in
macrophages thereby favor bacterial growth.
PKCd / macrophagesmodestly decreasedMtb growth in
the presence of Ox-LDLs
Of interest, from decreased lipids in lungs (Figure 3f), macro-
phages (Figure 6d), and serum fatty acids (Figure 5c,d) of
PKCd / mice, we asked whether foam cell formation using
oxidized low-density lipoproteins (Ox-LDLs) would control
the growth of Mtb in otherwise susceptible PKCd /
macrophages. Upon pretreatment with Ox-LDLs, we found
significantly decreased bacterial growth (Figure 7i) and
NO production (Supplementary Figure S4d) in PKCd /
macrophages when compared with wild-type cells. Further-
more, Ox-LDLs pre-treated PKCd / macrophages revealed
Figure 5 Decreased serum fatty acids bymetabolic analysis followingMycobacterium tuberculosis (Mtb) infection. (a,b) Principal component analysis
(PCA) plots with percentage variation for each PC are indicated in parenthesis on the respective axis at 4 and 8 weeks after infection (1,000 colony-
forming units (CFUs)). (c, d) Serum levels (mg l1) of selected host-protective (arachidonic acid, a-linolenic acid, and palmitic acid) and host-detrimental
fatty acids (behenic acid, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA)) duringMtb infection at 4 and 8weeks after infection. Data are
represented as mean±s.d. of n¼4–5 mice/group. Data are analyzed using univariate and multivariate statistical techniques (PCA powers40.5, PLS-
DAVIP41.0, effect size40.8, and Student’s t-test po0.05) vs. wild-type (WT) control mice. Individual fatty acid levels are analyzed by Student’s t-test,
*Po0.05, **Po0.01.
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a modest decrease in growth of Mtb when compared with
untreated PKCd / cells (Figure 7i). On the other hand,
wild-type macrophages in the presence of Ox-LDLs showed
a significant increase in bacterial growth when compared
with untreated wild-type cells (Figure 7i). In addition,
Ox-LDLs increased lipid accumulation in wild-type macro-
phages but not in PKCd / macrophages (Supplemen-
tary Figure S4e).
Moreover, we evaluated the effect of an unsaturated (oleic
acid), saturated (palmitic acid) fatty acids, and native-LDLs on
PKCd / macrophages. In contrast to Ox-LDLs, we found
a significant increase in growth of Mtb in PKCd /
macrophages (Supplementary Figure S4c) with a conco-
mitant decrease in production of NO (Supplementary
Figure S4d) in the presence of oleic acid and native-LDLs.
Interestingly, macrophages treated with palmitic acid had no
effect on Mtb growth (Supplementary Figure S4c). Further-
more, macrophages treated with oleic acid, palmitic acid, and
native-LDLs had no major effect on lipid accumulation
(Supplementary Figure S4e). Collectively, these findings
suggest that fatty acids have a differential effect on the
PKCd signaling during mycobacterial growth in vitro and
might not be a major contributing factor for increased
mycobacterial burdens observed in vivo.
DISCUSSION
We have demonstrated the functional role of PKCd in host
defense against Mtb infection in humans and mice. PKCd is
highly expressed in human whole blood during active TB
disease progression as well as within the Mtb-specific proin-
flammatory regions of necrotic and cavitary lung granulomas
during TB disease. These regions of high proinflammatory
signatures are required for an early control of bacterial
replication and could lead to necrotic damage (caseation)
Table 1 Serum fatty acid concentrations (mg l 1) for wild type and PKCd / at 4 weeks after infection










Conc s.d. Conc s.d.
Docosanoic acid (behenic acid) 0.72 0.19 0.51 0.13 — 1.124 0.535 1.301 1.41
Eicosanoic acid (arachidic acid) 6.52 2.51 3.44 1.91 — 1.228 0.597 4.474 1.90
Heneicosanoic acid 0.22 0.08 0.16 0.06 — — — 1.169 1.38
Heptadecanoic acid (margaric acid) 19.73 1.58 11.09 4.15 0.007 2.084 0.638 5.681 1.78
Pentadecanoic acid (pentadecylic acid) 5.30 0.97 4.25 0.94 — 1.090 0.615 1.001 1.25
Tetracosanoic acid (lignoceric acid) 8.71 11.65 1.69 0.57 — — — 2.957 5.15
Hexadecanoic acid (palmitic acid) 2.14 0.57 1.68 0.66 — — 0.504 1.212 1.27
Nonadecanoic acid 0.11 0.02 0.04 0.07 — 1.060 0.663 — 2.75
Octadecanoic acid (stearic acid) 1.65 0.28 1.50 0.68 — — 0.550 — 1.10
11-Eicosenoic acid 9.52 2.66 6.37 2.59 — 1.183 0.638 3.209 1.49
10-Heptadecenoic acid 1.88 0.45 1.32 0.52 — 1.069 0.568 1.771 1.42
13-Docosenoic acid (erucic acid) 0.41 0.13 0.21 0.08 0.026 1.487 — 2.571 1.95
15-Tetracosenoic acid (nervonic acid) 3.55 5.62 1.63 0.97 — — — 1.869 2.18
Undecenoic acid 0.79 0.16 0.52 0.22 — 1.196 0.548 2.063 1.52
9,12,15-Octadecatrienoic acid
(a-linolenic acid)
1.26 0.35 0.64 0.21 0.012 1.797 0.740 3.179 1.97
8,11,14-Eicosatrienoic acid
(homo-g-linolenic acid)
3.08 0.52 1.93 0.67 0.017 1.724 0.661 5.487 1.60
5,8,11,14-Eicosatretraenoic acid
(arachidonic acid)
3.10 0.92 1.74 1.92 — — 0.515 2.430 1.78
11,14-Eicosadienoic acid (homo-g-linoleic
acid)
5.77 1.16 4.95 1.85 — — 0.585 — 1.17
4,7,10,13,16,19-Docosahexaenoic acid
(cervonic acid)
0.31 0.08 0.18 0.06 0.024 1.546 — 1.597 1.72
5,8,11,14,17-Eicosapentaenoic acid
(timnodonic acid)
16.14 5.14 9.91 3.20 — 1.213 — 1.481 1.63
5,8,11-Eicosatrienoic acid (mead acid) 0.09 0.02 0.15 0.05 — 1.037 — — 0.60
9-Octadecenoic acid (oleic acid) 358.02 213.1 240.62 97.38 — — — 1.311 1.49
9,12-Octadecadienoic acid (linoleic acid) 1.43 0.30 0.99 0.63 — — 0.694 — 1.44
Abbreviations: Conc, concentration; PCA, principal component analysis; PLS-DA VIP, partial least square discriminant analysis variable importance in the projection;
PKCd / , protein kinase-Cd-deficient.
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and consequent cavity formation if not appropriately regu-
lated.30 Evidently, PKCdwasmore abundant in the caseous and
cavitary regions in this study, colocalizing with antimicro-
bial signatures21 and the regions of abundant lipids in
granulomas.31 However, it is not clear whether mediators of
inflammation and antimicrobials are responsible for the
overwhelming inflammation at the site of infection, or they
are remnants of a robust immune response meant to eliminate
Figure 6 Increasedmycobacterial growth and decreased lipid bodies in protein kinase-Cd (PKCd)-deficient macrophages. (a) Expression of PKCd and
other isoforms in bonemarrow-derivedmacrophages (BMDMs) infectedwith anHN878 strain ofMycobacterium tuberculosis (Mtb) fromCAGEstudy. (b)
PKCdmRNAexpressionduringH37RvMtb infection inBMDMsusingquantitative reverse transcription–PCR (qRT-PCR). (c) IncreasedgrowthofH37Rv
Mtb (multiplicity of infection (MOI)¼2) in macrophages deficient for PKCd during the course of infection. (d, e) PKCd / and wild-type (WT) BMDMs
were infected with green fluorescent protein (GFP)-expressingMtb (green, H37Rv) and stained with Oil Red O (red) for visualization and determination
of intracellular bacteria and quantification of lipid bodies (inset is bright-field view). (f–i) Cell-free supernatants from infectedmacrophageswere analyzed
for the production of tumor necrosis factor (TNF), interleukin (IL)-12p40, IL-6, and IL-1b at indicated time points after infection by enzyme-linked
immunosorbent assay (ELISA). Data are represented asmean±s.e.m. of quadruplicate and representative of three independent experiments. Data are
analyzed using unpaired Student’s t-test, *Po0.05, **Po0.01, ***Po0.001, vs. WT control macrophages.
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the pathogen in the lung. Consistently, we found PKCd as an
indicator of lung inflammation in yet another whole-blood
transcriptome data set from pulmonary infections such as
sarcoidosis, TB, pneumonia, and lung cancer.32 Given the
nonspecificity to TB and substantial overlap in PKCd
expression between our cohorts, this kinase offers a limitation
to be used as a prognostic marker. Distinctly using mass
spectrometry, we showed that the expression of PKCd varies
within the regions of lung granuloma. Notably, anti-TB therapy
decreased PKCd expression in whole blood of human patients,
reflecting a potential role for this protein kinase as a host factor
regulating Mtb-driven inflammation.
Our findings revealed that PKCd is indeed associated with
host defense against murine TB as PKCd ablation enhanced
Figure 7 Decreased production of killing effector molecules with no effect on phagosome maturation and autophagy in protein kinase-Cd-deficient
(PKCd / ) macrophages. (a, b) Western blot and densitometry analysis of phagosome (LAMP-1, LAMP-3, and Cathepsin-D (Cath D)) and autophagy
(LC3-II) markers in total macrophage cell lysates followingMycobacterium tuberculosis (Mtb) infection. (c, d) Impaired production of nitric oxide in PKCd
macrophages measured by Griess reagent assay and quantitative reverse transcription–PCR (qRT-PCR). (e, f) Deficiency of PKCd resulted in
decreasedproduction of hydrogenperoxide (H2O2) and reactive oxygen species (ROS). (g) Percentage of live, dead, andapoptoticmacrophages (Mphs)
after 3 days of infection determined by Annexin V and 7-aminoactinomycin (7-AAD) staining. (h) Supernatants from 3-day-infected wild-type (WT) and
PKCd / macrophageswere exchanged on 4 h-infected PKCd / (WTSN) andWT (PKCd / SN)macrophages to determine bacterial growth at day
3 after infection. (i) Macrophages from wild-type and PKCd / mice were pretreated with or without oxidized low-density lipoproteins (Ox-LDLs)
overnight. Cells were then infected with Mtb-containing medium with or without Ox-LDLs for 3 days to determine mycobacterial growth. Data are
represented as mean±s.e.m. of quadruplicate and are representative of three independent experiments. Data are analyzed using unpaired Student’s
t-test, *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001, vs. WT control macrophages.
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mortality with rapid weight loss, high bacterial loads, and
exacerbated lung pathology. In these mice, we found higher
levels of lung proinflammatory cytokines duringMtb infection,
consistent with our published reports on the role of PKCd in
listeriosis7 and cutaneous leishmaniasis.6 Remarkably, inhibi-
tion of PKCd using a specific peptide inhibitor TatVd1.1
(ref. 23) recapitulated aggravated lung inflammation in
PKCd / mice during Mtb infection, revealing a direct role
of this kinase in regulation of lung inflammation.
Alveolar macrophages (AMs) are essential for protection
during Mtb infection in mice,33 and we found strikingly
reduced numbers of AMs with concomitantly higher lung
bacterial loads that could lead to necrosis in PKCd / mice.
To control enhanced bacterial burdens, activated macrophages
and monocytes are recruited that perhaps explain excessive
NO oxide in the PKCd / lungs, in contrast to PKCd /
macrophages in vitro. Notably, mice deficient in AMs due to
the deletion of granulocyte-macrophage colony-stimulating
factor develop a disorder of accumulated surfactant lipids in
the alveolar spaces of the lungs.34 Despite reduced AMs in
PKCd / mice, we did not observe increased lipid staining in
the lungs. This could be due to the increased recruitment of
activated macrophages that catabolize surfactant lipids along
with type II alveolar epithelial cells.35 Importantly, it is feasible
Table 2 Serum fatty acid concentrations (mg l 1) for the wild type and PKCd / mice at 8 weeks after infection










Conc s.d. Conc s.d.
Docosanoic acid (behenic acid) 0.90 0.38 0.40 0.18 — 1.304 0.604 4.487 2.25
Eicosanoic acid (arachidic acid) 7.49 2.96 2.60 0.15 0.045 1.652 0.623 7.334 2.88
Heneicosanoic acid 0.24 0.12 0.10 0.07 — 1.143 — 4.287 2.40
Heptadecanoic acid (margaric acid) 16.89 2.03 9.50 7.71 — 0.958 0.730 2.763 1.78
Tetradecanoic acid (myristic acid) 32.83 5.04 19.14 1.29 0.010 2.719 — 5.197 1.72
Undecenoic acid 0.93 0.13 0.40 0.49 — 1.077 0.840 5.312 2.33
Hexadecanoic acid (palmitic acid) 27.84 18.68 13.07 8.88 — — — 3.674 2.13
Pentadecanoic acid (pentadecylic acid) 6.97 1.14 4.42 2.77 — 0.918 0.636 3.733 1.58
Tridecanoic acid (tridecylic acid) 0.67 0.11 0.52 0.15 — 1.067 — — 1.29
11-Eicosenoic acid 11.81 2.29 4.43 1.35 0.003 3.220 0.805 11.346 2.67
10-Heptadecenoic acid 2.83 0.27 1.41 0.74 0.026 1.906 0.659 7.442 2.01
13-Docosenoic acid (erucic acid) 0.69 0.25 0.16 0.02 0.024 2.126 0.760 12.574 4.31
15-Tetracosenoic acid (nervonic acid) 1.16 0.44 0.38 0.44 0.046 1.767 — — 3.05
9-Octadecenoic acid (oleic acid) 0.23 0.05 0.82 0.35 0.042 1.695 — 3.912 0.28
Palmitelaidic acid 0.13 0.04 0.05 0.03 0.019 2.014 0.763 6.327 2.60
9,12,15-Octadecatrienoic acid
(a-linolenic acid)
1.96 0.53 0.39 0.49 0.005 2.961 0.768 13.193 5.03
4,7,10,13,16,19-Docosahexaenoic acid
(cervonic acid)
0.14 0.10 0.05 0.11 — 0.814 0.570 — 2.80
8,11,14-Eicosatrienoic acid
(homo-g-linolenic acid)
2.59 0.49 2.11 0.43 — 0.993 — — 1.23
9,12-Octadecadienoic acid
(linoleic acid)
1.37 0.41 0.68 0.20 0.037 1.660 0.692 1.293 2.01
5,8,11,14-Eicosatretraenoic acid
(arachidonic acid)
1.24 0.11 0.89 0.22 0.042 1.588 0.603 — 1.39
11,14-Eicosadienoic acid
(homo-g-linoleic acid)
7.22 1.09 2.77 2.77 0.042 1.606 0.602 7.822 2.61
4,7,10,13,16,19-Docosahexaenoic acid
(cervonic acid)
91.98 10.89 50.86 21.39 0.022 1.923 0.555 2.858 1.81
5,8,11,14,17-Eicosapentaenoic acid
(timnodonic acid)
17.46 2.21 7.06 7.53 — 1.382 0.709 2.715 2.47
5,8,11-Eicosatrienoic acid (mead acid) 0.25 0.11 1.20 0.76 — 1.245 0.590 10.320 0.21
9-Hexadecenoic acid (palmitolinoleic acid ) 38.79 5.85 23.81 8.47 0.031 1.769 — 1.387 1.63
Abbreviations: Conc, concentration; PCA, principal component analysis; PLS-DA VIP, partial least square discriminant analysis variable importance in the projection;
PKCd / , protein kinase-Cd-deficient.
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that due to higher bacterial burden AMs decreased in
PKCd / mice. Consequently, increased inflammatory cell
recruitment to the lungs as a result of proinflammatory
cytokines, which in turn might have decreased alveolar spaces
(for gas exchange), translated in the mortality in these mice
during Mtb infection. Our findings suggest that PKCd is
required for maintenance of an optimal inflammatory balance
during Mtb infection that is a key factor in limiting immun-
opathology to host lung tissue. We infer from these findings
where PKCd ablation inmice renders them hypersusceptible to
TB, and therefore it is likely that increased expression (blood)
and abundance (granulomas) of this kinase reflect its role as a
host factor to contain ongoing inflammation in humans.
Host lipid bodies provide an excellent nutrient source for the
survival of intracellular Mtb,36 thereby decreasing its own
metabolism37 that allows pathogenesis38 and persistence12,39,40
of the bacterium. The necessity of triacylglycerol for slow
replication was demonstrated in a recent study where
deposition of excessive triacylglycerol inMtb bacterium slowed
down its growth as opposed to aMtb strain capable of pumping
out lipids.41 Reports have indicated a critical role of PKCd in the
accumulation of cholesterol in human22 and mouse15 macro-
phages and triacylglycerol during glucose intolerance induced
by high-fat diet in PKCd / mice.10 Corroborating with these
findings, we found that PKCd is indeed critical for the
accumulation of lipids in the lungs,macrophages, and to a lesser
extent in the case of serum fatty acids followingMtb infection.
The latter may not contribute much to the biological relevance
owing to subtle differences. Notably, it has been shown that in
steady state, absence of PKCd is dispensable for the uptake of
Ox-LDL to induce foam cell formation in murine and human
macrophages.42
Moreover, our observations of Mtb loads in PKCd /
macrophages pretreatedwith unsaturated, saturated fatty acids,
and oxidized and native LDLs supported that lipid accumula-
tion might not necessarily contribute to the intracellular
bacterial growth in macrophages deficient for PKCd. Recently,
it was shown that increased lipids in lungs and macrophages
drive the polarization of macrophages (M2) involved in
fibrosis.43 In PKCd / mice, the decreased availability of
lipids and enhanced proinflammatory cytokines might have
limited tissue repair processes in the lungs. Thus, lipid
accumulation can be the consequence rather than the cause
of susceptibility to Mtb infection in PKCd / mice. This
Mtb-driven modulation of host lipids may be the means by
which this highly evolved pathogen controls its replication rate
in vivo. It is feasible that inability of PKCd / mice to
accumulate intracellular lipids hampers the ability of Mtb to
undergo slow-replicative state during infection.
Intracellular Mtb can be eliminated by the induction of
macrophage phagosome maturation44 and autophagy.45 The
PKC isoforms, including b27 and a,28 were reported to be
important for maturation of Mtb-containing phagosomes. In
contrast to PKCb and PKCa, our findings indicated that PKCd
is dispensable for phagosome maturation and autophagy in
Mtb-infected macrophages. An alternative explanation is that
PKCd, unlike other isoforms (a, b, and g), is insensitive to
calcium signaling46 that is important for phagosome matura-
tion. Another isoform PKCz has been implicated as a key factor
for TLR2-ERK1/2 (Toll-like receptor 2/extracellular signal-
regulated kinase 1/2)-mediated secretion of TNF in both
murine and human macrophages following Mtb infection
in vitro.47 However, inhibition of PKCd with rottlerin
abrogated apoptosis in murine macrophages when cultured
with cell-free supernatant of Mycobacterium indicus pranni
(Mw).48 In contrast, we observed increased apoptosis in
PKCd / macrophages following Mtb infection. This obser-
vation strengthens accumulating evidence regarding the
nonspecific actions of rottlerin as a PKCd inhibitor.13,42
As we found no effect on phagosome maturation and
autophagy, we probed other effector functions in which PKCd
might be involved. It is well established that within macro-
phages, Mtb can be successfully eradicated by oxidative (ROS,
H2O2) and nitrosative (NO) killing functions.
29 Interestingly,
IFN-g-activated macrophages synergistically increase NO
production by fivefold upon phorbol 12-myristate 13-acet-
ate-mediated PKC activation inMycobacterium bovis (Bacillus
Calmette–Gue´rin (BCG))-infectedmacrophages.49 Indeed, this
was confirmed in our study as the presence of PKCd enhanced
killing effector functions, whereas the absence thereof inhibited
these effector responses, thereby reducing the mycobacterial
killing capacity of PKCd / macrophages. To our knowledge,
there has been no report on a functional role for PKCd in
immunity to TB in mice and humans.
Collectively, our data revealed that PKCd is an indicator of
inflammation in both systemic and local tissue compartments
during active TB disease progression in humans. Global
deletion of PKCd worsens the Mtb disease outcome in mice
that exaggerated mortality with a shift toward increased
bacterial burdens, exacerbated pathology, and excessive
proinflammatory responses. To a lesser extent following
Mtb infection, decreased lipids in lungs and macrophages
of PKCd / mice might further reduce the possibility for this
bacterium to undergo persistence. Mechanistically, reduced
killing effector functions in macrophages increased suscept-
ibility toMtb in the absence of PKCd. Taken together, the onset
of active humanMtb disease correlates with PKCd expression,
and conferring from our murine model, PKCd might be a
critical factor employed by the host to control exacerbation of
Mtb infection.
METHODS
Whole-blood mRNA signature of PKC. For whole-blood tran-
scriptomics, we analyzed the publicly available RNA-sequencing data
set from the Adolescent Cohort Study.19 We determined expression
profiles of all PKC isoforms from 800 days before diagnosis of TB
disease. A detailed description of the study and analysis is mentioned
in Supplementary Methods.
A cross-sectional cohort of TB disease and healthy control
participants. This was a cross-sectional study of 30 healthy
HIV-negative adults with latent Mtb infection and 30 HIV-negative
adults with active pulmonary TB disease recruited from the Western
Cape region of South Africa. The human Study protocol (HEC: 288/
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2008) was approved by the University of Cape Town, Human Ethics
Committee. Participants were recruited following written informed
consent before inclusion in the study. Latent Mtb infection was
diagnosed by QuantiFERON TB Gold in-tube assay (Qiagen, Hilden,
Germany, IFN-g levels40.35 IUml 1) andTBdisease was diagnosed
as sputum-positive positive Xpert MTB/RIF test (Cepheid, Sunnyvale,
CA). Whole blood in PAXgene blood RNA tubes (PreAnalytix,
Hombrechtikon, Switzerland) was collected from each participant.
Human PKCd expression following treatment and lung proteomics
from treatment-refractory TB patients. The blood gene signature
from the publically available data set in the NCBI-GEO (National
Center for Biotechnology Information Gene Expression Omnibus)
database, accession number GSE31348, was used to analyze PKC
expression of all isoforms during TB treatment.20 For human lung
proteomics, we analyzed the available data that have been deposited
into the PRIDE partner repository with the data set identifier
PXD003646. The heat map plot was constructed by calculating
z-scores of PKCd abundance in different types of granulomas derived
from multidrug-resistant TB patients. Details of the patients and
surgical procedures have been described previously.21
Mice. PKCd-deficient (PKCd / ) mice on the 129Sv genetic
background (8–12 weeks) were maintained under specific pathogen-
free conditions in individually ventilated cages. All experiments were
performed in accordance with the South African National Guidelines
and University of Cape Town practice for laboratory animal pro-
cedures. The protocol (AEC: 012/036) was approved by the Animal
Ethics Committee, Faculty of Health Sciences, University of Cape
Town, Cape Town, South Africa.
Mtb infection and determination of bacterial loads in mice. Mtb
(H37Rv) was grown to log phase in 7H9 complete media, and stocks
were prepared for infections via an intranasal route as described
previously.50 Bacterial loads in lungs and spleen ofMtb-infected mice
were determined at indicated time points after infection. Briefly,
organs from killed mice were removed aseptically, weighed, and
homogenized in 0.04% Tween-80. Tenfold dilutions were plated onto
Middlebrook 7H10 (BD Biosciences, San Jose, CA) agar plates
supplemented with 10% OADC and 0.5% glycerol and incubated at
37 1C for 21 days before colonies were counted.
Histopathology, immunohistochemistry, and lipid staining of the
lungs. Formalin-fixed (10%) lung tissue from Mtb-infected mice was
cut into 3 mm sections and stained with hematoxylin and eosin for
histopathological analysis. For iNOS staining, immunohistochemistry
was performed using rabbit anti-mouse iNOS (Abcam, Cambridge,
UK) as described previously.51 Neutral lipids were analyzed in lung
sections of Mtb-infected mice or macrophages by Oil Red O (Sigma-
Aldrich, St. Louis, MO) staining for 5min following washing and then
a rinse with 60% isopropanol.52 Sections were mounted using the
gelatine-based mounting medium. Image acquisition and quantifi-
cation of lesion area, iNOS staining, and area covered by lipid bodies
were performed on a Nikon (Tokyo, Japan) 90i microscope using NIS
advanced software.
Cytokine responses and immune cell populations in lungs using
fluorescence-activated cell sorting. Supernatants from lung
homogenates were collected for the determination of cytokines. IFN-g,
TNF, IL-6, IL-10 (all from BD Biosciences, San Jose, CA), IL-1b (R&D
Systems, Minneapolis, MN), and IFN-b (Biolegend, San Diego, CA)
productions were quantified in these supernatants by enzyme-linked
immunosorbent assay. Single-cell suspension of Mtb-infected lungs
was prepared following collagenase digestion as previously descri-
bed.51 Cells were then stained for lymphocytes (CD4þ , CD8þ T cells
and B cells) andmyeloid populations (alveolar macrophages, activated
macrophages, dendritic cells, and neutrophils). Surface phenotyping of
various cell populations was performed using the following antibodies:
CD3-FITC, CD4-PE, CD8-APC, CD19-PerCP, CD11c-APC, CD11b-
PE, MHCII-FITC, Siglec-F-PE, and Gr-1-FITC (all from BD Bios-
ciences). Cells were acquired on a FACS Calibur and the data were
analyzed using FlowJo software (v10.1, Tree Star, Ashland, OR) as
described previously.51
Metabolome analysis in serum of PKCd mice using gas
chromatography–mass spectrometry. Extraction of the collected
serum samples fromMtb-infected PKCd / and wild-type mice at 4
and 8 weeks after infection was performed as previously described53
using 50 ml of 0.45 mgml 1 3-phenylbutyric acid (Sigma-Aldrich) as
an internal standard before gas chromatography by gas chromato-
graphy with time-of-flight mass spectrometry (GCGC-TOFMS)
analyses. A detailed description is included in Supplementary
Methods.
Mtb infection in vitro. Murine BMDMs and human MDMs were
generated as previously described.50 Macrophages were pretreated
with either Ox-LDLs (100 mgml 1), native-LDLs (125 mgml 1), oleic
acid (500 mM), palmitic acid (500 mM), or left untreated overnight. Cells
were then infected in the presence of treatment(s) with Mtb (H37Rv,
unless otherwise indicated) with multiplicity of infection of 2. At
indicated time points, cells were lysed in 0.1% Triton X-100 for
determination of bacterial growth or fixed using 4%paraformaldehyde
for visualization of bacteria and Oil Red O staining. Images were
acquired using a Carl Zeiss 510 (Jena, Germany) confocal microscope
and bright-field images were analyzed for the area under the lipid stain
as mentioned above.
Quantitative RT-PCR fromwhole blood, humanMDMs, andmurine
BMDMs. A total of 16 RNA samples from QuantiFERON (QFT,
Qiagen, Hilden, Germany)-positive and -negative and 8 TB progressor
subjects were validated for the expression of PKCd using qRT-PCR
from the Adolescent Cohort Study. RNA was extracted from whole
blood (PAXgene blood RNA kit, Qiagen) followed by complementary
DNA synthesis using Superscript II Reverse Transcriptase (Life
Technologies, Waltham, MA).Mtb-infected BMDMs or MDMs were
reverse transcribed byTranscriptor First-Strand complementaryDNA
Synthesis Kit (Roche, Basel, Switzerland). Real-time PCR was per-
formed with LightCycler 480 SYBR Green I Master mix using a
LightCycler 480 II (Roche) for relative expression of PKCd relative to
HPRT housekeeping gene.
Western blot analysis. Sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and western blot analysis was performed as previously
described.50 Briefly, macrophages (3 106) were infected withMtb at
multiplicity of infection of 2 for 4 h. Cells were washed and then lysed
with ice-cold RIPA buffer containing protease inhibitors for 30min at
4 1C. Total cell lysates were analyzed for protein contents using BCA
assay (ThermoFisher, Waltham, MA). An equal amount of protein
(40 mg) was then electrophoresed on 12% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and transferred to a nitrocellulose
membrane (Sigma). The membrane was probed with anti-LAMP-1,
LAMP-3, Cathepsin-D, LC3-II, and GAPDH primary antibodies
diluted (1:200) in blocking buffer at 4 1C overnight. The membrane
was then incubated with the horseradish peroxidase-conjugated
secondary antibody (1:10,000) for 1 h at room temperature in blocking
buffer. Immunoblots were developed using Super Signal West Dura
substrate (Pierce, Waltham, MA).
Measurements ofNO,H2O2, ROS, andOilRedOstaining inBMDMs.
Cell supernatants from infected macrophages were collected for
measurement of NO using Griess reagent. H2O2 release from mac-
rophages was measured using colorimetric detection kit (Amplex Red
Hydrogen Peroxide Assay, ThermoFisher). ROS was determined in
macrophages using nitroblue tetrazolium (NBT, Sigma-Aldrich) that
is reduced to a dark-blue insoluble formazan. Cells were incubated for
phosphate-buffered saline containing 0.2%NBT for 90min. Formazan
was dissolved in 0.04% HCL in isopropanol, and the absorbance was
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determined at 560 nm.54 Quantification of Oil Red O staining in
macrophageswas determined following solubilizing of lipid droplets in
isopropanol and the absorbance was determined at 490 nm.55
Statistics. All data were analyzed using GraphPad Prism v 6.0
(GraphPad, La Jolla, CA) and Student’s t-test (two-tailed with unequal
variance) unless otherwise stated. A P value of 0.05 was considered
significant. Statistics regarding RNA-sequencing data analysis is
included in Supplementary Methods.
SUPPLEMENTARYMATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
ACKNOWLEDGMENTS
We thank the University of Cape Town (UCT) Animal Unit staff, Rodney
Lucas for technical assistance, Faried Abbas for maintenance of the BSL3
facility, Nazila Ghodsi, Munadia Ansari, and Fadwah Booley for genotyping
of mice and maintenance of laboratory, respectively. We also thank Lizette
Fick, Marilyn Tyler, and Zoe Lotz for their histology services. We thank Dirk
M. Lang andSusanCooper for Department of Science andTechnology and
National Research Foundation (DST-NRF) core confocal microscope
service and facility. This workwas supported by postdoctoral fellowship(s),
Arturo Falaschi Post-doctoral fellowship (ICGEB), Claude Leon Foundation
and Centre for Infectious Disease Research Initiative (CIDRI)–Wellcome
Trust (084323) to S.P.P., South African Medical Research Council (SAMRC)
Unit on Immunology of Infectious Diseases to F.B., NRF Competitive
Programme for Unrated Researchers (CSUR) and DST/NRF postgraduate
training program to R.G., National Research Funding (NRF) and South
African Research Chair initiative (SARCHi) to F.B. at the UCT, South Africa,
NRF and SAMRC funding to M.J.M. The human work was supported by
grants from the Bill and Melinda Gates Foundation (BMGF) Global Health
grantsOPP1021972, theNational InstitutesofHealth (RO1-AI087915;U19-
AI106761), and the Strategic Health Innovation Partnerships (SHIP) Unit of
the South African Medical Research Council with funds received from the
South African Department of Science and Technology and NIH-funded
Omics for TB Disease progression grant (NIH/NIAID U19 AI106761).
AUTHOR CONTRIBUTIONS
Conceptualization: S.P.P., M.O., R.G., and F.B.; methodology: S.P.P., M.O.,
M.J.M., D.T.L., R.H., D.B., M.V.R., D.E.Z. and F.D.; investigation: S.P.P.,
M.O., M.J.M., D.T.L., D.E.Z., S.K.M., A.P.N. and T.J.S.; writing-original
draft: S.P.P; writing-review and editing: S.P.P., M.O., M.J.M., R.H., D.T.L.,
D.E.Z., A.P.N., T.J.S., R.G., and F.B.; funding acquisition: R.G. and F. B.;
Resources, M.L., M.J.M., D.T.L., W.E.H., T.J S. and F.B.; supervision: F.B.
DISCLOSURE
The authors declared no conflict of interest.
Official journal of the Society for Mucosal Immunology
REFERENCES
1. Denning,M.F., Dlugosz, A.A., Threadgill, D.W.,Magnuson, T. &Yuspa, S.H.
Activation of the epidermal growth factor receptor signal transduction
pathway stimulates tyrosine phosphorylation of protein kinase C delta.
J. Biol. Chem. 271, 5325–5331 (1996).
2. Brodie,C. &Blumberg, P.M.Regulation of cell apoptosis byprotein kinasec
delta. Apoptosis 8, 19–27 (2003).
3. Jackson, D.N. & Foster, D.A. The enigmatic protein kinaseCdelta: complex
roles in cell proliferation and survival. FASEB J. 18, 627–636 (2004).
4. Page, K. et al. Regulation of airway smooth muscle cyclin D1 transcription
by protein kinaseC-delta.Am. J. Respir. CellMol. Biol. 27, 204–213 (2002).
5. De Servi, B., Hermani, A., Medunjanin, S. & Mayer, D. Impact of PKCdelta
on estrogen receptor localization and activity in breast cancer cells.
Oncogene 24, 4946–4955 (2005).
6. Guler, R. et al. PKCdelta regulates IL-12p40/p70 production by macro-
phages and dendritic cells, driving a type 1 healer phenotype in cutaneous
leishmaniasis. Eur. J. Immunol. 41, 706–715 (2011).
7. Schwegmann, A. et al. Protein kinase C delta is essential for optimal
macrophage-mediated phagosomal containment of Listeria monocyto-
genes. Proc. Natl. Acad. Sci. USA 104, 16251–16256 (2007).
8. Mecklenbrauker, I., Saijo, K., Zheng, N.Y., Leitges, M. & Tarakhovsky, A.
Protein kinase Cdelta controls self-antigen-induced B-cell tolerance.
Nature 416, 860–865 (2002).
9. Miyamoto, A. et al. Increased proliferation of B cells and auto-immunity
in mice lacking protein kinase Cdelta. Nature 416, 865–869 (2002).
10. Frangioudakis, G. et al. Diverse roles for protein kinase C delta and protein
kinase C epsilon in the generation of high-fat-diet-induced glucose
intolerance in mice: regulation of lipogenesis by protein kinase C delta.
Diabetologia 52, 2616–2620 (2009).
11. Garton, N.J. et al. Cytological and transcript analyses reveal fat and lazy
persister-like bacilli in tuberculous sputum. PLoS Med. 5, e75 (2008).
12. Russell, D.G., Cardona, P.J., Kim, M.J., Allain, S. & Altare, F. Foamy
macrophages and the progression of the human tuberculosis granuloma.
Nat. Immunol. 10, 943–948 (2009).
13. Tapia, J.A., Jensen, R.T. & Garcia-Marin, L.J. Rottlerin inhibits stimulated
enzymatic secretion and several intracellular signaling transduction
pathways in pancreatic acinar cells by a non-PKC-delta-dependent
mechanism. Biochim. Biophys. Acta 1763, 25–38 (2006).
14. Contreras, X., Mzoughi, O., Gaston, F., Peterlin, M.B. & Bahraoui, E.
Protein kinase C-delta regulates HIV-1 replication at an early post-entry
step in macrophages. Retrovirology 9, 37 (2012).
15. Wang, Y. & Oram, J.F. Unsaturated fatty acids phosphorylate and
destabilize ABCA1 through a protein kinase C delta pathway. J. Lipid
Res. 48, 1062–1068 (2007).
16. Larsen, E.C. et al. Differential requirement for classic and novel PKC
isoforms in respiratory burst and phagocytosis in RAW 264.7 cells.
J. Immunol. 165, 2809–2817 (2000).
17. Comalada, M., Xaus, J., Valledor, A.F., Lopez-Lopez, C., Pennington,
D.J. & Celada, A. PKC epsilon is involved in JNK activation that mediates
LPS-induced TNF-alpha, which induces apoptosis in macrophages.
Am. J. Physiol. Cell Physiol. 285, C1235–C1245 (2003).
18. Strasser, D. et al. Syk kinase-coupled C-type lectin receptors engage
protein kinase C-sigma to elicit Card9 adaptor-mediated innate immunity.
Immunity 36, 32–42 (2012).
19. Zak, D.E. et al. A blood RNA signature for tuberculosis disease risk: a
prospective cohort study. Lancet 387, 2312–2322 (2016).
20. Cliff, J.M. et al. Distinct phases of blood gene expression pattern through
tuberculosis treatment reflect modulation of the humoral immune
response. J. Infect. Dis. 207, 18–29 (2013).
21. Marakalala, M.J. et al. Inflammatory signaling in human tuberculosis
granulomas is spatially organized. Nat. Med. 22, 531–538 (2016).
22. Ma, H.T. et al. Protein kinase C beta and delta isoenzymes mediate
cholesterol accumulation in PMA-activated macrophages. Biochem.
Biophys. Res. Commun. 349, 214–220 (2006).
23. Pabla, N. et al. Inhibition of PKCdelta reduces cisplatin-induced
nephrotoxicity without blocking chemotherapeutic efficacy in mouse
models of cancer. J. Clin. Invest. 121, 2709–2722 (2011).
24. Ichi, I. et al. Identification of genes andpathways involved in the synthesis of
Mead acid (20:3n-9), an indicator of essential fatty acid deficiency.
Biochim. Biophys. Acta 1841, 204–213 (2014).
25. Anes, E., Kuhnel, M.P., Bos, E., Moniz-Pereira, J., Habermann, A. &
Griffiths, G. Selected lipids activate phagosome actin assembly and
maturation resulting in killing of pathogenic mycobacteria. Nat. Cell Biol. 5,
793–802 (2003).
26. FANTOM Consortium and the RIKEN PMI and CLST (DGT) et al.
A promoter-level mammalian expression atlas. Nature 507, 462–470
(2014).
27. Daniel, D.S. et al. The reduced bactericidal function of complement
C5-deficient murine macrophages is associated with defects in the
synthesis and delivery of reactive oxygen radicals to mycobacterial
phagosomes. J. Immunol. 177, 4688–4698 (2006).
28. Chaurasiya, S.K. & Srivastava, K.K. Downregulation of protein kinase
C-alpha enhances intracellular survival of Mycobacteria: role of PknG.
BMC Microbiol. 9, 271 (2009).
29. Nathan, C. & Shiloh, M.U. Reactive oxygen and nitrogen intermediates
in the relationship between mammalian hosts and microbial pathogens.
Proc. Natl. Acad. Sci. USA 97, 8841–8848 (2000).
ARTICLES
510 VOLUME 11 NUMBER 2 | MARCH 2018 |www.nature.com/mi
30. Tobin, D.M. et al. Host genotype-specific therapies can optimize the
inflammatory response to mycobacterial infections. Cell 148, 434–446
(2012).
31. Kim, M.J. et al. Caseation of human tuberculosis granulomas
correlates with elevated host lipid metabolism. EMBO Mol. Med. 2,
258–274 (2010).
32. Bloom, C.I. et al. Transcriptional blood signatures distinguish pulmonary
tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers.PLoS
ONE 8, e70630 (2013).
33. Gonzalez-Juarrero,M. et al.Disruption of granulocytemacrophage-colony
stimulating factor production in the lungs severely affects the ability of
mice to control Mycobacterium tuberculosis infection. J. Leukoc. Biol. 77,
914–922 (2005).
34. Dranoff, G. et al. Involvement of granulocyte-macrophage colony-stimulat-
ing factor in pulmonary homeostasis. Science 264, 713–716 (1994).
35. Malloy, J.L. &Wright, J.R. In vivo clearance of surfactant lipids during acute
pulmonary inflammation. Respir. Res. 5, 8 (2004).
36. Peyron, P. et al. Foamy macrophages from tuberculous patients’
granulomas constitute a nutrient-rich reservoir for M. tuberculosis
persistence. PLoS Pathog. 4, e1000204 (2008).
37. Caceres, N. et al. Evolution of foamy macrophages in the pulmonary
granulomas of experimental tuberculosis models. Tuberculosis (Edinb) 89,
175–182 (2009).
38. Marrero, J., Rhee, K.Y., Schnappinger, D., Pethe, K. & Ehrt, S.
Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is
critical for Mycobacterium tuberculosis to establish andmaintain infection.
Proc. Natl. Acad. Sci. USA 107, 9819–9824 (2010).
39. Daniel, J., Maamar, H., Deb, C., Sirakova, T.D. & Kolattukudy, P.E.
Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid
droplets and acquires a dormancy-like phenotype in lipid-loaded
macrophages. PLoS Pathog. 7, e1002093 (2011).
40. Pandey, A.K. & Sassetti, C.M. Mycobacterial persistence requires the
utilization of host cholesterol. Proc. Natl. Acad. Sci USA 105, 4376–4380
(2008).
41. Martinot, A.J. et al.Mycobacterial metabolic syndrome: LprG and Rv1410
regulate triacylglyceride levels, growth rate and virulence inMycobacterium
tuberculosis. PLoS Pathog. 12, e1005351 (2016).
42. Szilagyi, K. et al. PKCdelta is dispensible for oxLDL uptake and foam cell
formation by human and murine macrophages. Cardiovasc. Res. 104,
467–476 (2014).
43. Romero, F. et al.Apneumocyte-macrophage paracrine lipid axis drives the
lung toward fibrosis. Am. J. Respir. Cell Mol. Biol. 53, 74–86 (2015).
44. MacMicking, J.D., Taylor, G.A. & McKinney, J.D. Immune control of
tuberculosis by IFN-gamma-inducible LRG-47. Science 302, 654–659
(2003).
45. Gutierrez, M.G., Master, S.S., Singh, S.B., Taylor, G.A., Colombo, M.I. &
Deretic, V. Autophagy is a defense mechanism inhibiting BCG and
Mycobacterium tuberculosis survival in infected macrophages. Cell 119,
753–766 (2004).
46. Kazanietz, M.G. et al. Characterization of ligand and substrate specificity
for the calcium-dependent and calcium-independent protein kinase C
isozymes. Mol. Pharmacol. 44, 298–307 (1993).
47. Yang, C.S. et al. Protein kinase C zeta plays an essential role for
Mycobacterium tuberculosis-induced extracellular signal-regulated kinase
1/2 activation in monocytes/macrophages via Toll-like receptor 2.
Cell Microbiol. 9, 382–396 (2007).
48. Pandey, R.K., Bhatt, K.H., Dahiya, Y. & Sodhi, A. Mycobacterium indicus
pranii supernatant induces apoptotic cell death in mouse peritoneal
macrophages in vitro. PLoS ONE 6, e17093 (2011).
49. Olivier, M. et al. Phenotypic difference between Bcg(r) and Bcg(s)
macrophages is related to differences in protein-kinase-C-dependent
signalling. Eur. J. Biochem. 251, 734–743 (1998).
50. Parihar, S.P. et al. Statin therapy reduces the mycobacterium tuberculosis
burden in human macrophages and in mice by enhancing autophagy and
phagosome maturation. J. Infect. Dis. 209, 754–763 (2014).
51. Guler, R. et al. IL-4Ralpha-dependent alternative activation of macro-
phages is not decisive for Mycobacterium tuberculosis pathology and
bacterial burden in mice. PLoS ONE 10, e0121070 (2015).
52. Fowler, S.D. & Greenspan, P. Application of Nile red, a fluorescent
hydrophobic probe, for the detection of neutral lipid deposits in tissue
sections: comparison with oil red O. J. Histochem. Cytochem. 33,
833–836 (1985).
53. Williams, R. et al.Amulti-analytical platform approach to themetabonomic
analysis of plasma from normal and Zucker (fa/fa) obese rats.Mol. Biosyst.
2, 174–183 (2006).
54. Furukawa, S. et al. Increased oxidative stress in obesity and its impact on
metabolic syndrome. J. Clin. Invest. 114, 1752–1761 (2004).
55. Lee, Y.J. et al. Antioxidant activity and anti-adipogenic effects of wild herbs
mainly cultivated in Korea. Molecules 18, 12937–12950 (2013).
This work is licensed under a Creative Commons
Attribution4.0InternationalLicense.Theimagesor
otherthirdpartymaterialinthisarticleareincludedinthearticle’s
Creative Commons license, unless indicated otherwise in the
credit line; if the material is not included under the Creative
Commons license, userswill need to obtain permission from the
license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2018
ARTICLES
MucosalImmunology | VOLUME 11 NUMBER 2 | MARCH 2018 511
